Status:
COMPLETED
Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Hemophilia B
Allergic Reactions
Eligibility:
All Genders
Brief Summary
Retrospective, multicenter study in patients with hemophilia B. This study will be placed at 20 to 50 hemophilia treatment centers in North America and the EU, and is designed to estimate the frequenc...
Eligibility Criteria
Inclusion
- Written consent to release patient information
- Living or deceased patients with mild to severe hemophilia B who have had at least 1 exposure to replacement factor IX product(s).
- Living or deceased patients who had their first infusion of any FIX product between 1 January 1991 and 31 December 2003.
Exclusion
- There are no exclusion criteria.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
End Date :
November 1 2007
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT00195221
Start Date
February 1 2005
End Date
November 1 2007
Last Update
December 5 2007
Active Locations (38)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85016
2
Orange, California, United States, 92868
3
Atlanta, Georgia, United States, 30322
4
Boise, Idaho, United States, 83712